Serum Sclerostin and Risk of Hip Fracture in Older Caucasian Women
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
CONTEXT: Sclerostin, a protein secreted by osteocytes, inhibits bone formation. Individuals with genetic mutations that decrease the availability of sclerostin have very high bone mass. OBJECTIVE: The aim of this study was to examine the hypothesis that elevated serum sclerostin levels are associated with increased risk of hip fracture in older women. DESIGN, SETTING, AND PARTICIPANTS: This was a case-cohort study of a prospective, community-based cohort of 9704 women aged 65 yr or older. Sclerostin levels were measured in serum collected in 1989-1990 in 228 women with incident hip fractures and 227 women in a randomly selected sample; average follow-up time was 9.8 yr. RESULTS: Serum sclerostin levels were correlated with total hip bone mineral density (BMD; r = 0.27, P < 0.001). The risk of hip fracture increased across quartiles of serum sclerostin (test for trend, P < 0.001) and was significantly elevated among those in the fourth quartile (hazard risk 3.4, 95% confidence interval 1.7-7.0) compared with women in the lowest quartile, after adjusting for age, body mass index, estrogen use, history of fracture since age 50 yr, and total hip BMD. When dividing the cohort into eight groups by sclerostin quartile and median hip BMD, women with lower total hip BMD in the highest sclerostin quartile had a 22.3-fold (95% confidence interval 5.8-86.3) increased risk of fracture compared with women with higher total hip BMD in the lowest sclerostin quartile. CONCLUSIONS: We conclude that higher serum sclerostin levels are associated with a greater risk of hip fractures in older women. In addition, the risk of hip fracture is amplified when high sclerostin levels are combined with lower BMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 1×
“In nonhuman studies, sclerostin has been shown to decrease osteoblast differentiation and mineralization and increase mature osteoblast apoptosis (4, 14, 15).”
BackgroundIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 1×
“been identified in patients with the autosomal recessive conditions sclerosteosis and van Buchem disease (8, 9).”
BackgroundSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442 · cited 1×
“been identified in patients with the autosomal recessive conditions sclerosteosis and van Buchem disease (8, 9).”
BackgroundGaudio, A., Pennisi, P., Bratengeier, C., Torrisi, V., Lindner, B., Mangiafico, R. A., Pulvirenti, I., Hawa, G., Tringali, G., & Fiore, C. E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0067 · Cited by 315 · cited 1×
“sclerostin levels (18), which may increase the risk for hip”
BackgroundWinkler, D. G., Sutherland, M. S. K., Ojala, E., Turcott, E., Geoghegan, J. C., Shpektor, D., Skonier, J. E., Yu, C., & Latham, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m400524200 · Cited by 164
Research works printed but not linked: 13
- Johnell, 2004, An estimate of the worldwide prevalence, mortality and disability associated with hip fracture., Osteoporos Int, 15, 897
- Lewiecki, 2003, Nonresponders to osteoporosis therapy., J Clin Densitom, 6, 307
- Chapurlat, 2005, Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial., Osteoporos Int, 16, 842
- Winkler, 2003, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist., EMBO J, 22, 6267
- Padhi, 2011, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody., J Bone Miner Res, 26, 19
- Prentice, 1986, A case-cohort design for epidemiologic cohort studies and disease prevention trials., Biometrika, 73, 1
- Hamersma, 2003, The natural history of sclerosteosis., Clin Genet, 63, 192
- Drake, 2010, Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women., J Clin Endocrinol Metab, 95, 5056
- Sutherland, 2004, Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation., Bone, 35, 828
- Mödder, 2011, Relation of age, gender, and bone mass to circulating sclerostin levels in women and men., J Bone Miner Res, 26, 373
- Polyzos, 2012, Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide., Osteoporos Int, 23, 1171
- Mirza, 2010, Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women., J Clin Endocrinol Metab, 95, 1991
- Mödder, 2011, Regulation of circulating sclerostin levels by sex steroids in women and in men., J Bone Miner Res, 26, 27
Cited by
A road map for understanding molecular and genetic determinants of osteoporosis
Yang, T.-L., Shen, H., Liu, A., Dong, S.-S., Zhang, L., Deng, F.-Y., Zhao, Q., & Deng, H.-W. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0282-7 · Cited by 341
The clinical utility of bone marker measurements in osteoporosis
Wheater, G., Elshahaly, M., Tuck, S. P., Datta, H. K., & van Laar, J. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-201 · Cited by 322
“BMD and BTMs are independent predictors of fracture risk, recent evidence does not support the use of BTMs to select the optimal treatment, but BTMs can be used to monitor treatment efficacy before BMD changes can be evaluated.”
BackgroundInfluentialThe role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
Sclerostin in excessive drinkers: relationships with liver function and body composition
Martín González, C., Fernández Rodríguez, C. M., Abreu González, P., García Rodríguez, A., Alvisa Negrín, J. C., Cabañas Perales, E., González Navarrete, L., Vera Delgado, V. E., Ortega Toledo, P., & González Reimers, E. (2022) · Nutrients · doi:10.3390/nu14132574 · Cited by 9
Metadata
- Authors
- Arasu, A., Cawthon, P. M., Lui, L.-Y., Do, T. P., Arora, P. S., Cauley, J. A., Ensrud, K. E., Cummings, S. R., & The Study of Osteoporotic Fractures Research Group
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-06-01
- Volume
- 97
- Issue
- 6
- Pages
- 2027-2032
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2067171323
- Cited by
- 119
- References
- 7
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.